Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of acotiamide in esophagogastric junction outflow obstruction (EGJOO)
jRCT2071210072Phase 2Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of acotiamide in esophagogastric junction outflow obstruction (EGJOO) (3 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Primary: Proportion of patients with improvement in sensation of food sticking in chest at 4 weeks (Treatment Period 1). Started Oct 2021; status: completed.
02
Drugs
acotiamide
03
Conditions
esophagogastric junction outflow obstruction (EGJOO)
Beyond the preview
Go deeper on jRCT2071210072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210072.